Humira and biosimilars — CareFirst (Caremark)
immune checkpoint inhibitor-related toxicity (inflammatory arthritis)
Initial criteria
- Member has moderate or severe immunotherapy-related inflammatory arthritis AND (inadequate response to corticosteroids or conventional synthetic drug such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine OR intolerance/contraindication to these agents)
Approval duration
12 months